In vivo T-cell depletion using anti-thymocyte globulin (ATG) is widely used in allogeneic hematopoietic stem cell transplantation (HSCT) for prophylaxis of GvHD. We investigated the influence of thymoglobulin dose (an ATG) on GvHD following matched sibling donor (MSD) HSCT with a busulfan and fludarabine preparative regimen. Medical records of 180 patients who received MSD HSCT with a conditioning regimen of busulfan, fludarabine, and ATG (BuFluATG) were reviewed retrospectively. The median age was 53 years (range 18-68). Initial diagnoses were acute myeloid leukemia (73.3%) and myelodysplastic syndrome (26.7%). Forty-four and 68 patients (24.4 and 37.7%) experienced acute and chronic GvHD of any grade, respectively. High-dose (⩾4.5 mg/kg) ATG was independently associated with decreased risk of acute GvHD (hazard ratio = 0.36, 95% confidence interval (CI): 0.15-0.84, P = 0.019) compared to low-dose ATG (o4.5 mg/kg). Although ATG dose was associated with the risk of acute GvHD, it was not associated with the risk of chronic GvHD in our study. A higher dose (⩾4.5 mg/kg) of ATG decreases the risk of acute GvHD but had no significant impact on disease-free survival in MSD HSCT patients conditioned with BuFluATG. The optimal dose of ATG should be further investigated in a large prospective study context.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is an essential treatment option for patients with hematologic malignancies. 1 Allogeneic HSCT is the only available treatment modality for cure of relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). However, the high rate of non-relapse mortality following allogeneic HSCT remains a major hurdle. 2 GvHD is a common cause of non-relapse mortality following allogeneic HSCT. Anti-thymocyte globulin (ATG) has been proven effective for GvHD prophylaxis in haploidentical 3 or unrelated 4 allogeneic HSCT, which have a high risk of GvHD. ATG has also been shown to reduce the risk of chronic GvHD (CGvHD) following matched sibling donor (MSD) or matched unrelated donor HSCT. 5 The effectiveness of ATG in GvHD prophylaxis in HLA-identical sibling donor peripheral blood stem cell transplantation with a myeloablative preparative regimen was confirmed via a randomized controlled phase III trial of patients in complete remission from acute leukemia. 6 In that trial, ATG-Fresenius (ATG-F) at a total dose of 30 mg/kg (10 mg/kg/day for 3 days) was tested. However, relapse-free survival (RFS) was similar in groups patients treated with and without ATG treatment.
Concern regarding the increased risk of relapse potentially induced by T-cell depletion in patients treated with ATG has also been raised, as evidence about the protective role of ATG against GvHD has accumulated. European guidelines propose 2.5 mg/kg/ day for 3 days (total dose, 7.5 mg/kg) of thymoglobulin or 10 mg/ kg/day for 3 days (total dose, 30 mg/kg) of ATG-F for HLA-matched sibling or unrelated allogeneic HSCT irrespective of the intensity of conditioning. 7 Some experts have suggested that ⩽ 7.5 mg/kg of thymoglobulin may suffice for HLA-MSD HSCT, 8 but the appropriate dose of ATG remains controversial.
To address these concerns, we investigated the effect of thymoglobulin dose on the risk of GvHD in HLA-matched sibling allogeneic HSCT.
PATIENTS AND METHODS Patients
We performed a retrospective review of the medical charts of 180 patients with AML or MDS who underwent allogeneic MSD HSCT at 10 institutions from 2007 to 2014. All investigators were experienced in performing allogeneic HSCT and managing GvHD. Our inclusion criteria were (1) allogeneic HSCT from an HLA-MSD, (2) busulfan and fludarabine (BuFlu) conditioning, and (3) GvHD prophylaxis using thymoglobulin. Patients who underwent mismatched family or unrelated donor HSCT, or who received a second or third allogeneic HSCT were excluded.
Conditioning
Data were collected from patients undergoing BuFlu conditioning using three doses of busulfan: two doses of reduced intensity (3.2 mg/kg and 6.4 mg/kg) and myeloablative (12.8 mg/kg). Once daily busulfan was given at 0.8 mg/kg from day − 6 to day − 3 (total dose, 3.2 mg/kg), and then once daily 3.2 mg/kg of busulfan was given for 2 days (total dose, 6.4 mg/kg). A myeloablative dose of bulsulfan was given as 3.2 mg/kg once daily for 4 days. Rabbit ATG (Thymoglobulin) was administered to all patients. Thymoglobulin was given as an equally divided dose for 2 or 3 days from day − 3. The relationship between ATG dose and transplant outcome was calculated based on the total dose of ATG, using a cut-off of 4.5 mg/kg to separate high-dose and low-dose groups based on a previous phase III randomized trial. 4 Calcineurin inhibitors and/or short-term methotrexate were used as immunosuppressants.
Analysis of GvHD outcomes
Consensus grading criteria 9 were used to grade AGvHD, and cumulative incidence was calculated through day 100. CGvHD was assessed using traditional grading criteria. 10 Patients whose GvHD status could not be determined were excluded. Competing risk regression analysis was used to investigate the relationship between variables and cumulative risk of GvHD as described by Fine and Gray, 11 with death without GvHD as the competing event. All clinically relevant variables were included in multivariate analysis for competing risk of acute and CGvHD. non-relapse mortality was analyzed using competing regression analysis as well, with relapse as the competing event.
Statistical analysis
Statistical analysis was performed using STATA 13 (Stata Corp., College Station, TX, USA). The median potential follow-up time was determined using the Kaplan-Meier method. 12 Overall survival (OS) was calculated from the date of allogeneic HSCT to the date of last follow-up or death from any cause. relapse-free survival was calculated from the date of allogeneic HSCT to the date of disease relapse or death from any cause. Cox regression analysis was performed for RFS and OS using the same variables as used in GvHD analysis.
RESULTS

Patient and HSCT characteristics
A total of 180 patients who were diagnosed with AML or MDS and underwent HLA-identical sibling allogeneic HSCT were included (Table 1) . Median age was 53 years (range 18-68), male gender was more frequent (60.6%). Most patients (73.3%) were diagnosed with AML, and 90% of patients underwent chemotherapy prior to allogeneic HSCT. Underlying disease was uncontrolled in 36.7% of patients at the time of transplantation. In busulfan dose analysis, three dose groups were used: one myeloablative (12.8 mg/kg, 12.2%), and two reduced intensity doses (6.4 mg/kg in 75% and 3.2 mg/kg in 12.8%). The fludarabine dose ranged from 120 to 200 mg/m 2 of which 180 mg/m 2 was the most frequently used (82%). The median total dose of ATG used in the study population was 4.5 mg/kg (range 2.0-9.0). In ATG dose analysis, 4.5 mg/kg was used as the cut-off between high-and low-dose groups. 4 Stem cells were mobilized for collection by G-CSF in all patients.
Transplant outcomes Median follow-up duration was 28.0 months (95% CI: 26.0-36.0). AGvHD of any grade occurred in 44 patients (24.4%), while grade II or greater AGvHD occurred in 28 patients (15.6%). CGvHD occurred in 68 patients (37.7%), with a median day of occurrence of 158 days (interquartile range 102-281). Extensive stage CGvHD (25.0%) was more common than limited stage (12.8%). Relapse occurred in 68 patients, and 27 patients died without relapse.
GvHD A myeloablative dose of busulfan (12.8 mg/kg) was associated with increased risk of AGvHD compared to a 3.2 mg/kg dose of busulfan in univariate and multivariate analysis (hazard ratio (HR) = 2.74 and 5.96, 95% CI: 0.85-8.90 and 0.87-10.06, P = 0.093 and 0.026, respectively) ( Table 2) . A reduced dose of busulfan (6.4 mg/kg) was not significantly associated with increased risk of AGvHD (HR = 2.96, 95% CI: 0.87-10.06, P = 0.081). High-dose ATG (⩾4.5 mg/kg) led to decreased risk of AGvHD compared to low- Figure 1b) . The only factor significantly associated with risk of CGvHD was disease status prior to HSCT (HR = 3.36, 95% CI: 1.02-11.07, P = 0.046 for non-complete remission).
Survival Seventy-two patients (40.0%) died during the follow-up period in our study. Fifteen patients treated with low-dose ATG relapsed (26.8%), and the non-relapse mortality rate was 17.9% (10 patients) in the low-dose ATG group. In the high-dose ATG group, 28 patients experienced relapse (22.6%), while 19 patients (15.3%) died from a cause other than relapse. The cause of death did not vary between the two groups (P = 0.69).
Higher busulfan doses (6.4 or 12.8 mg/kg) were associated with lower risk for RFS compared to a 3.2 mg/kg dose of busulfan (HR = 0.33 and 0.28, 95% CI: 0.12-0.89 and 0.08-0.93, P = 0.029 and 0.039 for 6.4 mg/kg and 12.8 mg/kg, respectively) ( Table 3) . A high-dose ATG (⩾4.5 mg/kg) was associated with an increased HR for RFS in multivariate analysis compared with a low dose, although this difference was not statistically significant (HR = 2.13, 95% CI: 0.96-4.72, P = 0.063).
The only factor correlated with OS in multivariate analysis was disease status prior to HSCT (HR = 2.09, 95% CI: 1.12-3.87, P = 0.020) (Table 3) . However, there were differences in OS between high-and low-dose ATG in patients in remission and those not in remission in our study. In those in remission, the ATG o4.5 mg/kg group showed significantly higher survival rates (Figures 2a, P = 0.026) . In patients not in remission, the ATG4 4.5 mg/kg group showed higher survival rates, but without statistical significance (Figure 2b , P = 0.076). Patients with AML exhibited a slightly increased HR for OS compared to patients with MDS or ABO incompatibility, but these differences were not statistically significant.
Recipient and donor age were significantly associated with OS in univariate analysis (HR = 1.70 and 1.65, 95% CI: 1.04-2.77 and 1.02-2.66, P = 0.035 and 0.041, respectively), but not in multivariate analysis.
DISCUSSION
AGvHD and CGvHD are the leading causes of non-relapse mortality following allogeneic HSCT. In vivo T-cell depletion using ATG-F has been shown to reduce the risks of AGvHD and CGvHD in unrelated HSCT. 13 This finding was confirmed for rabbit ATG (thymoglobulin), which is now the only GvHD drug available in Europe and Asia. 4 Our study demonstrated that a high dose (⩾4.5 mg/kg) of rabbit ATG reduces the risk of AGvHD following HLA-MSD HSCT using BuFlu conditioning with no significant effect on RFS and OS.
ATG treatment prior to allogeneic HSCT is associated with lower GvHD-related mortality, lower risk of CGvHD, and lower risk of AGvHD.
14 A recent randomized controlled phase III trial investigating the role of ATG in HLA-matched sibling HSCT with a myeloablative preparative regimen clearly demonstrated the protective effects of ATG for CGvHD, with a slight (not statistically significant) reduction in AGvHD. 6 Differences in AGvHD and CGvHD results between this trial and our study may be due to differences in preparative regimens and in ATG tapering schedules, which differ by institution.
Several retrospective studies have suggested that ATG reduces both acute and chronic GvHD following unrelated or related allogeneic HSCT. 13, 15, 16 However, these studies included mixed populations of MSD and matched unrelated donor. Another study concluded that using ATG in MSD-HSCT had no protective effect on acute or chronic GvHD 17 ; however, this study included a small number of patients (n = 45 in non-ATG group) and a nonhomogeneous study population with disease subgroups.
Underlying disease could also influence the effectiveness of ATG on CGvHD in MSD HSCT. While the previous phase III randomized study enrolled patients with acute leukemia including AML and acute lymphoblastic leukemia, 6 our study population was limited to myeloid malignancies (MDS and AML).
Determining the appropriate ATG dose is critical to improving HSCT outcomes. The European Society for Blood and Marrow Transplantation (EBMT) recommends an ATG dose of 7.5 mg/kg irrespective of conditioning regimen or source of donor. 7 However, several studies that analyzed data from the EBMT registry suggested that 46 mg/kg ATG increases the risk of relapse and reducese OS following matched related donor reduced intensity conditioning (MRD-RIC) HSCT. 18 A previous study showed that a 2-day total of 5 mg/kg ATG with BuFlu conditioning reduces the incidence and severity of acute and chronic GvHD without impairing disease control, 19 while a total of 2.5 mg/kg ATG was insufficient. We used 4.5 mg/kg as the cut-off for high-and low-ATG dose groups based on a previous large phase III randomized controlled trial. 4 The increased relapse associated with ATG treatment has become a major concern in allogeneic HSCT. Donor-derived T-cell depletion by ATG may lessen the GvL effect causing more frequent and earlier relapse. 20 Disease status (CR vs non-CR) before transplant between the two ATG groups was significantly different in our study population (Table 1) , which could reflect the treating physician's choice to maximize the GVL effect using a decreased ATG dose especially in patients with uncontrolled disease. In addition, we further analyzed whether the dose of ATG affected OS according to prior transplant status. In those with CR status, the survival rate was higher in the ATG o 4.5 mg/kg group, while in those with non-CR status, the survival rate was higher in the ATG44.5 mg/kg group. These results demonstrate the effect of ATG dose on survival according to CR status in patients before transplantation. In the pre-transplantation remission state, highdose ATG can interfere with the GvL effect and shorten OS. On the other hand, under non-CR conditions, the conditioning intensity of transplantation including ATG, may have influenced survival.
A recent review suggested that relapse due to ATG treatment is a concern mainly in an RIC setting. 8 In our study, subgroup analysis of patients who underwent reduced-intensity conditioning demonstrated that a high dose of ATG (⩾4.5 mg/kg) was not associated with risk of relapse (data not shown). Our study has several limitations. First, it provided no clear conclusion, a common limitation of retrospective studies. Second, the lack of detailed data on immunosuppressant tapering schedules for each patient makes it difficult to rule out the effects of different tapering schedules on CGvHD. Despite the retrospective nature of our study, we used relevant clinical factors as covariates to appropriately adjust the risk of GvHD, including: disease subtype; disease status before HSCT; busulfan, fludarabine and ATG dose; sex; ABO blood type mismatch; recipient and donor age; and infused CD34 + cell dose. These multivariate analyses reduce potential bias. 21 Furthermore, our study was strictly controlled in terms of ethnicity, HLA mismatch, origin of hematopoietic stem cells and preparative regimen composition.
In conclusion, this study suggests that acute GvHD can be prevented with thymoglobulin of 5 mg/kg (range: 4.5-9.0) in patients undergoing MSD HSCT, without a negative effect on relapse. Comparable survival is achieved with a lower dose of ATG, but such a dose is associated with higher risk of AGvHD. However, a thymoglobulin dose of 3.75 mg/kg (range: 2.0-4.0) may lead to superior survival in patients with pre-transplant remission.
The optimal dose of ATG that will reduce the risk of AGvHD and CGvHD without impairing outcomes in HLA-MSD HSCT should be investigated further in a large prospective study. 
